89 related articles for article (PubMed ID: 28159587)
1. Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas.
Costa Arantes DA; Gonçalves AS; Jham BC; Duarte ECB; de Paula ÉC; de Paula HM; Mendonça EF; Batista AC
Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Jun; 123(6):e188-e196. PubMed ID: 28159587
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical investigations on the expression of programmed cell death ligand 1, human leukocyte antigens G and E, and granzyme B in intraoral mucoepidermoid carcinoma.
Mosconi C; Arantes DAC; Gonçalves AS; Alencar RCG; Oliveira JC; Silva TA; Mendonça EF; Batista AC
Arch Oral Biol; 2017 Nov; 83():55-62. PubMed ID: 28711734
[TBL] [Abstract][Full Text] [Related]
3. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract][Full Text] [Related]
4. Immune response and evasion mechanisms in lip carcinogenesis: An immunohistochemical study.
Lopes MLDS; Gonzaga AKG; Mosconi C; Palomino GM; Mendonça EF; Batista AC; Silveira ÉJDD
Arch Oral Biol; 2019 Feb; 98():99-107. PubMed ID: 30468994
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.
Sabbatino F; Villani V; Yearley JH; Deshpande V; Cai L; Konstantinidis IT; Moon C; Nota S; Wang Y; Al-Sukaini A; Zhu AX; Goyal L; Ting DT; Bardeesy N; Hong TS; Fernandez-del Castillo C; Tanabe KK; Lillemoe KD; Ferrone S; Ferrone CR
Clin Cancer Res; 2016 Jan; 22(2):470-8. PubMed ID: 26373575
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
[TBL] [Abstract][Full Text] [Related]
7. [The Mechanism of HLA Class I and PD-L1 Expression of Cancer Cells in Tumor Microenvironment].
Mimura K; Shiraishi K; Kobayashi M; Kono T; Kono K
Gan To Kagaku Ryoho; 2016 Sep; 43(9):1027-9. PubMed ID: 27628542
[TBL] [Abstract][Full Text] [Related]
8. Expression of the nonclassical HLA-G and HLA-E molecules in laryngeal lesions as biomarkers of tumor invasiveness.
Silva TG; Crispim JC; Miranda FA; Hassumi MK; de Mello JM; Simões RT; Souto F; Soares EG; Donadi EA; Soares CP
Histol Histopathol; 2011 Dec; 26(12):1487-97. PubMed ID: 21972088
[TBL] [Abstract][Full Text] [Related]
9. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
Majzner RG; Simon JS; Grosso JF; Martinez D; Pawel BR; Santi M; Merchant MS; Geoerger B; Hezam I; Marty V; Vielh P; Daugaard M; Sorensen PH; Mackall CL; Maris JM
Cancer; 2017 Oct; 123(19):3807-3815. PubMed ID: 28608950
[TBL] [Abstract][Full Text] [Related]
10. Relevance of HLA-G, HLA-E and IL-10 expression in lip carcinogenesis.
Gonçalves AS; Oliveira JP; Oliveira CF; Silva TA; Mendonça EF; Wastowski IJ; Batista AC
Hum Immunol; 2016 Sep; 77(9):785-90. PubMed ID: 26723902
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis.
Slater NA; Googe PB
J Cutan Pathol; 2016 Aug; 43(8):663-70. PubMed ID: 27153517
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
[TBL] [Abstract][Full Text] [Related]
17. The clinicopathologic significance of the expression of HLA-G in oral squamous cell carcinoma.
Gonçalves AS; Wastowski IJ; Capeletti LR; Sacono NT; Cortez AP; Valadares MC; Silva TA; Batista AC
Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Mar; 117(3):361-8. PubMed ID: 24528793
[TBL] [Abstract][Full Text] [Related]
18. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.
Chang H; Jung W; Kim A; Kim HK; Kim WB; Kim JH; Kim BH
APMIS; 2017 Aug; 125(8):690-698. PubMed ID: 28493410
[TBL] [Abstract][Full Text] [Related]
20. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
